Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity

Authors: Aboli Bhingarkar, Yuyin Wang, Keito Hoshitsuki, Katherine Marie Eichinger, Sanjay Rathod, Yin Zhu, He Lyu, Andrew T. McNutt, Larry W. Moreland, Lee McDermott, David R. Koes, Christian A. Fernandez

Source: Frontiers in Pharmacology, Vol 15 (2025)

Subject Terms: rheumatoid arthritis, antidrug antibodies (ADA), NFAT (nuclear factor of activated T cells), methotrexate, adalimumab, duvelisib, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1397995/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/33b8517d55b4427c99069835ddbabc64

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids

Authors: Thomas S. Dexheimer, Zahra Davoudi, Nathan P. Coussens, Thomas Silvers, Joel Morris, Naoko Takebe, Rabih Said, Jeffrey A. Moscow, James H. Doroshow, Beverly A. Teicher

Source: SLAS Discovery, Vol 32, Iss , Pp 100222- (2025)

Subject Terms: PI3K, Spheroids, Inavolisib, Alpelisib, Copanlisib, Duvelisib, Medicine (General), R5-920, Biotechnology, TP248.13-248.65

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2472555225000152; https://doaj.org/toc/2472-5552

Access URL: https://doaj.org/article/f648a7870a4c429da63a3a3217e1dd06

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia

Authors: Jingmei Yang, Ran Friedman

Source: Cancer Cell International, Vol 23, Iss 1, Pp 1-15 (2023)

Subject Terms: Combination treatment, FLT3-ITD, Targeted therapy, Alpelisib, Duvelisib, Idelalisib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671

File Description: electronic resource

Relation: https://doaj.org/toc/1475-2867

Access URL: https://doaj.org/article/ef658aa5feb24b87b21ee90a4800d8c8

New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma

Authors: M. А. Sorokina, A. V. Rakhteenko, T. R. Grishina

Source: Фармакоэкономика, Vol 16, Iss 2, Pp 291-302 (2023)

Subject Terms: peripheral t cell lymphoma, azacitidine, duvelisib, romidepsin, bortezomib, biomarkers, personalized medicine, Therapeutics. Pharmacology, RM1-950, Economics as a science, HB71-74

File Description: electronic resource

Relation: https://www.pharmacoeconomics.ru/jour/article/view/807; https://doaj.org/toc/2070-4909; https://doaj.org/toc/2070-4933

Access URL: https://doaj.org/article/5a0887d944a34f6ea4c3e01ab3e566a0

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome

Authors: Surya K. De

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: idelalisib, duvelisib, copanlisib, alpelisib, leniolisib, phosphatidylinositol 3-kinase, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1337436/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/e1d3ff56115142b9b8643c2b2406099c

A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)

Authors: O. A. Rukavitsyn, V. P. Pop, M. V. Drozd, Yu. E. Ryabukhina

Source: Онкогематология, Vol 17, Iss 4, Pp 38-47 (2022)

Subject Terms: chronic lymphocytic leukemia, poor prognosis, richter’s syndrome, venetoclax, duvelisib, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://oncohematology.abvpress.ru/ongm/article/view/587; https://doaj.org/toc/1818-8346; https://doaj.org/toc/2413-4023

Access URL: https://doaj.org/article/71293a3716b04eab8727f25a1f7a4a4e

Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review

Authors: Duy C. Tran, MD, Maria Karim, BA, Kristen Lo Sicco, MD, Nooshin Brinster, MD, Emily C. Milam, MD, Ian W. Tattersall, MD, PhD

Source: JAAD Case Reports, Vol 24, Iss , Pp 97-100 (2022)

Subject Terms: duvelisib, follicular lymphoma, phosphoinositide 3-kinase inhibitor, PI3K inhibitor, pityriasis rubra pilaris, psoriasiform, Dermatology, RL1-803

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352512622001692; https://doaj.org/toc/2352-5126

Access URL: https://doaj.org/article/6f9564cd50a54717a95b93b6ed8735c2

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials

Authors: Zhongwang Wang, Hui Zhou, Jing Xu, Jinjin Wang, Ting Niu

Source: Frontiers in Immunology, Vol 13 (2023)

Subject Terms: dual PI3K-δ, γ inhibitor, duvelisib, lymphoid neoplasms, safety, efficacy, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1070660/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/ec113a69a3194e50829b933a6aa170bb

A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats

Authors: Sayed AY, Khalil NY, Almomen A, Alzoman NZ, Almehizia AA, Darwish IA

Source: Drug Design, Development and Therapy, Vol Volume 15, Pp 2667-2677 (2021)

Subject Terms: leukemia, phosphoinositide-3-kinase, duvelisib, human plasma, therapeutic drug monitoring, pharmacokinetic study, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/a-highly-sensitive-nonextraction-assisted-hplc-method-with-fluorescenc-peer-reviewed-fulltext-article-DDDT; https://doaj.org/toc/1177-8881

Access URL: https://doaj.org/article/aac1a01b390b4a65b80bcbabc803cc3d

Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome

Authors: Elghawy, Omar ^a, Yang, Austin G. ^a, Sussman, Jonathan H. ^a, Thomas, Colin J. ^a, Carter, Jordan S. ^a, Landsburg, Daniel J. ^a, Svoboda, Jakub ^a, Kim, Ellen ^b, Rook, Alain H. ^b, Chung, Jina ^b, Villasenor-Park, Jennifer ^b, Plastaras, John P. ^c, LaRiviere, Michael ^c, Hubbeling, Harper ^c, Chelius, Monica ^c, Nasta, Sunita D. ^a, Chong, Elise A. ^a, Schuster, Stephen J. ^a, Barta, Stefan K. ^{a, ∗}

Source: In Journal of the American Academy of Dermatology March 2025 92(3):634-636

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma

Authors: Sabrina Manni, Anna Fregnani, Laura Quotti Tubi, Zaira Spinello, Marco Carraro, Greta Scapinello, Andrea Visentin, Gregorio Barilà, Marco Pizzi, Angelo Paolo Dei Tos, Fabrizio Vianello, Renato Zambello, Carmela Gurrieri, Gianpietro Semenzato, Livio Trentin, Francesco Piazza

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: mantle cell lymphoma, CK1α, BCR inhibitors, ibrutinib, duvelisib, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.733848/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/c56d9b095bbc411ca2589e2e8f63ba58

Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma

Authors: Joo Hyun Kim, Won Seog Kim, Chaehwa Park

Source: BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)

Subject Terms: Lymphoma, PI3K, Copanlisib, Duvelisib, Drug resistance, IL-6, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12885-019-6057-7; https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/25e295b3f9cc4c06802b23951cf87152

Development and Validation of a Novel Microwell-Based Fluorimetric Method Assisted with Fluorescence Plate Reader for High-Throughput Determination of Duvelisib: Application to the Analysis of Capsules and Plasma Samples

Authors: Abdullah M. Al-Hossaini, Hany W. Darwish, Ahmed Y. Sayed, Nasr Y. Khalil, Rashad Al-Salahi, Ibrahim A. Darwish

Source: Applied Sciences, Vol 12, Iss 20, p 10460 (2022)

Subject Terms: duvelisib, fluorimetry, microwell-based methods, high throughput analysis, Copiktra® capsules, plasma, Technology, Engineering (General). Civil engineering (General), TA1-2040, Biology (General), QH301-705.5, Physics, QC1-999, Chemistry, QD1-999

File Description: electronic resource

Relation: https://www.mdpi.com/2076-3417/12/20/10460; https://doaj.org/toc/2076-3417

Access URL: https://doaj.org/article/62adad46a43949da9c395710850e7e2a

Development and Validation of 96-Microwell-Based Spectrophotometric and High-Performance Liquid Chromatography with Fluorescence Detection Methods with High Throughput for Quantitation of Duvelisib and Seliciclib in Their Bulk Forms and Capsules

Authors: Haya I. Aljohar, Abdulmajeed A. Alghamdi, Nasr Y. Khalil, Hany W. Darwish, Rashad Al-Salahi, Ibrahim A. Darwish

Source: Applied Sciences, Vol 12, Iss 20, p 10624 (2022)

Subject Terms: duvelisib, seliciclib, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, 96-microwell spectrophotometry, high performance liquid chromatography, high throughput pharmaceutical analysis, Technology, Engineering (General). Civil engineering (General), TA1-2040, Biology (General), QH301-705.5, Physics, QC1-999, Chemistry, QD1-999

File Description: electronic resource

Relation: https://www.mdpi.com/2076-3417/12/20/10624; https://doaj.org/toc/2076-3417

Access URL: https://doaj.org/article/99d018f12df14f11af8d8cde1c9639fe

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment

Authors: Otašević Vladimir, Mihaljević Biljana, Antić Darko

Source: Medicinski Podmladak, Vol 70, Iss 4, Pp 6-12 (2019)

Subject Terms: chronic lymphocytic leukemia, ibrutinib, venetoclax, idelalisib, duvelisib, Medicine

File Description: electronic resource

Relation: https://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2019/0369-15271904006O.pdf; https://doaj.org/toc/0369-1527; https://doaj.org/toc/2466-5525

Access URL: https://doaj.org/article/2fbe815eea8440ecb36ed58a6cb08ca1

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells

Authors: Jun‐ichi Kawada, Shotaro Ando, Yuka Torii, Takahiro Watanabe, Yoshitaka Sato, Yoshinori Ito, Hiroshi Kimura

Source: Cancer Medicine, Vol 7, Iss 4, Pp 1275-1284 (2018)

Subject Terms: Duvelisib, EBV, lymphoma, PI3k/Akt, PI3Kδ, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/98c50db023ee47708cb9f5e4ab5084a5

Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors

Authors: Kumudha Balakrishnan, Krishna Bojja, William Decker, Michael J. Keating

Source: European Medical Journal, Vol 2, Iss 1, Pp 24-30 (2017)

Subject Terms: chronic lymphocytic leukaemia (cll), phosphoinositide 3-kinase (pi3k), duvelisib (ipi-145), apoptosis, b cell receptor (bcr), microenvironment, bcr inhibitors, ibrutinib, idelalisib, Medicine

File Description: electronic resource

Relation: https://www.emjreviews.com/hematology/article/hide-and-seek-the-game-between-chronic-lymphocytic-leukaemia-cells-and-b-cell-receptor-signalling-inhibitors/; https://doaj.org/toc/2397-6764

Access URL: https://doaj.org/article/bb3a68bbf5d5452da51c47fa3994402a

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

Authors: Matthew D. Blunt, Andrew J. Steele

Source: Leukemia Research Reports, Vol 4, Iss 2, Pp 60-63 (2015)

Subject Terms: CLL, PI3K, Idelalisib, Duvelisib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2213048915300194; https://doaj.org/toc/2213-0489

Access URL: https://doaj.org/article/8ee28e57968345228ac7726633115143

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Authors: Daniel A. Rodrigues, Fernanda S. Sagrillo, Carlos A. M. Fraga

Source: Pharmaceuticals, Vol 12, Iss 2, p 69 (2019)

Subject Terms: approved drugs, duvelisib, Copiktra, FDA, phosphoinositide 3-kinases, cancer, Medicine, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://www.mdpi.com/1424-8247/12/2/69; https://doaj.org/toc/1424-8247

Access URL: https://doaj.org/article/0a4c3a45171f4b0f9fcd2ebb3b7fcee2

Verastem Oncology Highlights COPIKTRA Presentations at the International Workshop on Chronic Lymphocytic Leukemia

Source: Entertainment Close-up. September 28, 2019